All novel mass spectrometry data are available via PRIDE/ProteomeXchange (accession number PXD013040).

Introduction {#sec001}
============

By the time a protein is subjected to analysis, it can have acquired one or more covalent modifications. These could include modifications of biological origin, modifications introduced deliberately (e.g., to probe protein structure and function), and modifications occurring during sample preparation and storage. In bottom-up mass-spectrometry-based proteomics, where proteins are digested and analysed as peptides, prior knowledge of modifications can enable more of the acquired spectra to be identified \[[@pone.0235263.ref001]\]. Known or suspected modifications are specified as parameters of a database search, enabling more of the protein sequence to be mapped, and also allowing the modifications themselves to be localised and quantified. For partially characterised or unknown modifications, however, this approach is not practical: specifying a long list of variable modifications (e.g., as a way of capturing unknown modifications) would expand the database dramatically, lengthening the search duration and reducing the number of confidently identified spectra \[[@pone.0235263.ref002]\]. New types of search have been developed to address this problem \[[@pone.0235263.ref002]--[@pone.0235263.ref009]\]. They include 'open' database searches, which permit precursor ions with shifted masses \[[@pone.0235263.ref006]\]; and 'spectral pair' searches, in which unidentified spectra are matched to spectral libraries \[[@pone.0235263.ref005]\]. An example of the latter approach is dependent peptide (DP) searching \[[@pone.0235263.ref003]\]. In a typical case, a DP is a chromatographic feature that is not identified by a database search, but whose fragment-ion spectrum partially matches that of one of the search hits (the 'base' peptide). The DP is typically a modified form of the base peptide, and the two features' masses differ. In theory, some of the DP's product ions will be the same as the corresponding product ions of the base peptide, while others will display the mass difference (Δ*m*). Crucially, Δ*m* does not need to be specified *a priori*, as it is calculated for every pair of unidentified feature and database-search hit. Identifying features in this way can take much less time than a database search \[[@pone.0235263.ref003]\] but does confer certain limitations: sites that are fully occupied by unknown modifications cannot be detected; and overall sequence coverage is unlikely to be extended.

Originally implemented as a stand-alone tool (ModifiComb \[[@pone.0235263.ref003], [@pone.0235263.ref010]\]), DP searching has recently been incorporated into the MaxQuant software \[[@pone.0235263.ref011], [@pone.0235263.ref012]\]. Within MaxQuant, the DP search can utilise hits (i.e., potential base peptides) generated by the Andromeda search engine \[[@pone.0235263.ref013]\]. Studies utilising MaxQuant's DP search function have confirmed its potential to discover modifications \[[@pone.0235263.ref012], [@pone.0235263.ref014]--[@pone.0235263.ref021]\]. Lassak et al. used the function to analyse a bacterial translation elongation factor, and discovered a novel type of glycosylation \[[@pone.0235263.ref014]\]. Mordret et al. used the function to detect single amino acid substitutions, and also carried out a general test of its validity \[[@pone.0235263.ref012]\]. A large set of synthetic phosphopeptides and corresponding unmodified peptides was analysed, and the phosphoryl modifications were left for a DP search to find. The search identified over a thousand spectra as belonging to singly-phosphorylated peptides, and all of these were true positives \[[@pone.0235263.ref012]\]. Few studies, however, have explored DP search results in an untargeted way. In the present study, we sought to evaluate DP searching as a means of characterising *in vitro* modified proteins. First, we generated model data by analysing a model protein (bovine serum albumin, BSA) that had been treated with a protein-modifying reagent (*N*-ethylmaleimide, NEM). Then, we performed DP searches and attempted to rationalise the search results.

Visualisation tools can greatly facilitate the interpretation of proteomic mass spectrometry data and database search results \[[@pone.0235263.ref022]--[@pone.0235263.ref025]\]. We identified a need for tools that visualise DP search results, and to meet this need we wrote a set of five scripts in the R language \[[@pone.0235263.ref026]\]. Three of the scripts are for surveying distributions of DPs (i.e., are hypothesis-generating), and the other two are for pinpointing hypothesised modifications (i.e., are hypothesis-testing). Some of the scripts can enrich DPs for modifications that are unique to a test sample. Herein we report search results and visualisations for our own data, as well as for public data from two other studies \[[@pone.0235263.ref027], [@pone.0235263.ref028]\]. The results demonstrate how a combination of DP searching and visualisation can assist in the characterisation of *in vitro* modified proteins. The approach could be useful for characterising protein targets of enzyme activities and reactive small molecules.

Materials and methods {#sec002}
=====================

Preparation and analysis of modified BSA {#sec003}
----------------------------------------

BSA (1 mg mL^−1^) was reacted with NEM (1 mM) in potassium phosphate buffer (100 mM) at pH 7.4. Unreacted NEM was scavenged with 1,4-dithiothreitol (DTT). The protein was purified (buffer exchange), reduced (DTT), alkylated (iodoacetamide), purified again (acetone precipitation), and digested (trypsin). The peptides were analysed in duplicate (analytical replicates 1 and 2) by reversed-phase nano liquid chromatography (nanoACQUITY liquid chromatograph; Waters, Milford, Massachusetts, USA) with online data-dependent tandem mass spectrometry (Orbitrap Fusion Lumos mass spectrometer; ThermoFisher Scientific, Waltham, Massachusetts, USA). A control sample (untreated BSA) was also prepared and analysed. Further details of materials and methods can be found in [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"}. Data for NEM-treated and untreated BSA have been deposited in PRIDE/ProteomeXchange \[[@pone.0235263.ref029]\] (accession number PXD013040).

Public data {#sec004}
-----------

Further mass spectrometry data were obtained from PRIDE/ProteomeXchange \[[@pone.0235263.ref029]\]. Data were selected according to the following criteria: (i) experiment involving exposure of one or more proteins to a protein-modifying reagent; (ii) data collected using standard data-dependent acquisition mass spectrometry; (iii) control data and two replicates available (not an essential criterion); (iv) results of a variable-modification database search reported in the literature. The following files/groups of files met the criteria and were included in the present study (the selection was not exhaustive): DMF_Cofilin1A.raw from PRIDE project PXD008314 \[[@pone.0235263.ref027]\]; and 1362-cs774_0\_a.raw, 1364-cs774_0\_b.raw, 1380-cs774_5\_a.raw and 1382-cs774_5\_b.raw from PRIDE project PXD006663 \[[@pone.0235263.ref028]\]. Sequence data (\*.fasta files) were obtained from the RCSB Protein Data Bank \[[@pone.0235263.ref030]\] (accession numbers 4F5S \[[@pone.0235263.ref031]\] and 1S81 \[[@pone.0235263.ref032]\]) and UniProt \[[@pone.0235263.ref033]\] (accession numbers P02042, P02647, P02766, P02768, P02787, P45592 and P68871, and the UniProtKB/Swiss-Prot human proteome, 4^th^ June 2019). Where possible, sequences were obtained without extraneous elements such as signal peptides. The data from Protein Data Bank accession number 4F5S consisted of two identical sequences, and so one of these was removed. MaxQuant's database of contaminants \[[@pone.0235263.ref011]\] was used either as supplied or in an edited form (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"}).

Database searches and dependent peptide searches {#sec005}
------------------------------------------------

All searches were done in MaxQuant (Max Planck Institute of Biochemistry, version 1.6.0.1) \[[@pone.0235263.ref011]\]. Database searches were done using Andromeda \[[@pone.0235263.ref013]\]. Individual \*.raw files were searched against databases consisting of either a protein of interest plus potential contaminants (1 + 244 or 1 + 245 sequences) or the UniProtKB/Swiss-Prot human proteome plus potential contaminants (20,406 + 82 sequences). The *in silico* digestion was done in 'specific' mode, using 'Trypsin/P' as the enzyme, and allowing for a maximum of two missed cleavages. The maximum peptide mass was adjusted so as to include ≥95% of relevant theoretical peptides (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"}). The minimum peptide length was seven amino acid residues. Additional *in silico* digestions were done using PeptideMass \[[@pone.0235263.ref034]\] (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"}).

When the purpose of the database search was to discover potential base peptides, a minimal set of variable modifications (methionine oxidation and protein N-terminal acetylation) and an appropriate fixed modification (cysteine *S*-carbamidomethylation \[[@pone.0235263.ref028]\] or *S*-pyridylethylation \[[@pone.0235263.ref027]\]) were specified. When the purpose was instead to localise a particular modification (a variable-modification search), the fixed and variable modifications were adjusted accordingly (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"}). The maximum number of modifications per peptide was always five, and the 'second peptides' function was always enabled. DP searches were appended to their respective database searches by enabling the 'dependent peptides' function (false discovery rate of 1%, mass bin size of 0.0065 Da). Results of DP searches were obtained from allPeptides.txt files \[[@pone.0235263.ref011]\] and filtered as described below. For selected DPs, we investigated whether the same chromatographic feature could also be detected by a variable-modification search (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"}).

Development of visualisation tools {#sec006}
----------------------------------

All tools ([S1](#pone.0235263.s016){ref-type="supplementary-material"}--[S5 Scripts](#pone.0235263.s020){ref-type="supplementary-material"}) were developed in R for Windows (R Core Team, version 3.4.0 or later) \[[@pone.0235263.ref026]\] using functions from the base packages, plus the additional function *read*.*fasta* from the 'seqinR' package (version 3.3--6 or later) \[[@pone.0235263.ref035]\]. [S1](#pone.0235263.s016){ref-type="supplementary-material"}--[S4 Scripts](#pone.0235263.s019){ref-type="supplementary-material"} were developed and tested on a Dell desktop PC (Intel Core i5-7500 processor, 8 GB RAM) running Windows 10. [S5 Script](#pone.0235263.s020){ref-type="supplementary-material"} was developed and tested on a Toshiba laptop PC (AMD E1-2100 APU processor, 4 GB RAM) running Windows 8.1. Each script requires a set of search results (allPeptides.txt files), a protein sequence (\*.fasta file), and the identifier of a protein of interest (e.g., a UniProt identifier). The search results are filtered (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"} of Table B) and a table of DPs is prepared. DPs are localised to segments of the protein sequence using a 'sliding window' \[[@pone.0235263.ref036]\]. Different scripts require different numbers of allPeptides.txt files and process the data to different extents. [S1](#pone.0235263.s016){ref-type="supplementary-material"}, [S2](#pone.0235263.s017){ref-type="supplementary-material"} and [S3](#pone.0235263.s018){ref-type="supplementary-material"} Scripts are for surveying DPs' Δ*m* values; they return DP localisation plots and Δ*m* frequency histograms. [S4](#pone.0235263.s019){ref-type="supplementary-material"} and [S5](#pone.0235263.s020){ref-type="supplementary-material"} Scripts are for pinpointing particular modifications; they require an expected Δ*m* value, and they return plots of DPs' localisation probabilities \[[@pone.0235263.ref012]\]. [S2](#pone.0235263.s017){ref-type="supplementary-material"}, [S3](#pone.0235263.s018){ref-type="supplementary-material"} and [S4](#pone.0235263.s019){ref-type="supplementary-material"} Scripts have the ability to enrich the DPs for modifications that are unique to a test sample (see 'Results and discussion'). A set of notes explaining how the scripts work can be found in [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"} of Table C. We will endeavour to maintain the scripts' compatibility with relevant software, and to address any limitations that come to light. Any future versions of the scripts will be made available from <https://github.com/preston-gw/>.

The accuracy of the visualisations was tested by manually mapping selected DPs onto graphics generated by scripts (20 DPs across five graphics, all confirmed to have been mapped correctly). After this, no significant changes were made to either the main data processing code or the mapping code (changes to graphical parameters, for example, were permitted). Certain graphics were prepared in batches by iterating an appropriate script. Figures were prepared from R output files using Inkscape (Free Software Foundation, version 0.91 or later) and GNU Image Manipulation Program (GIMP Development Team, version 2.10.8) (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"}). Figures such as [S4 Fig](#pone.0235263.s004){ref-type="supplementary-material"} and [S8 Fig](#pone.0235263.s008){ref-type="supplementary-material"} are representative of the graphics generated by the scripts.

Visualisation tools' instructions for use {#sec007}
-----------------------------------------

1.  Open R (version 3.6.0 or later)

2.  Make sure that package 'seqinR' \[[@pone.0235263.ref035]\] is installed. Installation is achieved by entering *install*.*packages(\"seqinr\")* in the R console.

3.  Open the script within R (File \> Open script)

4.  Review the script and complete file paths as appropriate. Further instructions are included in the header and body of the script. Explanatory notes can be found in [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"} of Tables B and C.

5.  Save a copy of the script if desired (File \> Save as)

6.  Run the script (Edit \> Run all)

7.  A graphic should appear on-screen. The times taken to visualise our model data using one of the aforementioned PCs were as follows: [S1 Script](#pone.0235263.s016){ref-type="supplementary-material"}, 8 s (desktop); [S2 Script](#pone.0235263.s017){ref-type="supplementary-material"}, 27 s (desktop), [S3 Script](#pone.0235263.s018){ref-type="supplementary-material"}, 62 s (desktop); [S4 Script](#pone.0235263.s019){ref-type="supplementary-material"}, 16 s (desktop); [S5 Script](#pone.0235263.s020){ref-type="supplementary-material"}, 26 s (laptop).

Mass calculations {#sec008}
-----------------

Expected Δ*m* values were calculated in R (version 3.4.0 or later) \[[@pone.0235263.ref026]\] using monoisotopic masses from ChemDraw (various versions, PerkinElmer) or Unimod \[[@pone.0235263.ref037]\] (<http://www.unimod.org/masses.html>). Masses used for calculations were accurate to at least four decimal places. Δ*m* values mentioned in the text have been rounded to two decimal places.

Statistical methods {#sec009}
-------------------

Pairwise comparisons of Δ*m* frequency histograms were done using the *cor*.*test* function (Spearman method) in R (version 3.4.0) \[[@pone.0235263.ref026]\].

Results and discussion {#sec010}
======================

Exploration of model data {#sec011}
-------------------------

BSA was selected as a model protein because it is well-characterised and contains a number of nucleophilic (i.e., potentially modifiable) amino acid residues \[[@pone.0235263.ref038], [@pone.0235263.ref039]\]. NEM was selected as the protein-modifying reagent because it is reactive towards a variety of amino acid side chains (those of cysteine, lysine and histidine) \[[@pone.0235263.ref040]\]. We predicted that NEM would modify BSA's only reduced cysteine residue, Cys-34 \[[@pone.0235263.ref031]\], as well as one or more lysine and/or histidine residues. The primary products of the reaction of BSA with NEM were expected to be Michael adducts, in which a hydrogen atom of the protein has effectively been replaced by an *N*-ethylsuccinimidyl (NESyl) group (Δ*m* = +125.05 Da). NESyl groups attached to cysteine residues are susceptible to hydrolysis (additional Δ*m* = +18.01 Da) \[[@pone.0235263.ref041], [@pone.0235263.ref042]\], and we assumed that this would also be the case for NESyl groups attached to lysine or histidine residues. Additionally, sulfur atoms to which NESyl groups are attached may oxidise \[[@pone.0235263.ref041]\].

Large numbers of chromatographic features were detected in analyses of NEM-treated BSA (*N* ≥ 34,812), and also in analyses of untreated BSA (*N* ≥ 44,430). Five to six percent of the features (1958 ≤ *N* ≤ 2328) were identified by MaxQuant as either potential base peptides (Andromeda search hits, 23--25% of identified features) or DPs (75--77% of identified features) ([S1 Fig](#pone.0235263.s001){ref-type="supplementary-material"}). Peptides of BSA (95% of identified features) were 9--10 times as numerous as predicted by *in silico* digestion and oxidation (*N* = 218). The high ratio of observed to expected features implies that large numbers of modifications had occurred independently of NEM treatment (e.g., artefacts of sample preparation or modifications pre-existing in the BSA). The detection of so many 'background' modifications, although difficult to account for, is consistent with Nielsen and coauthors' estimate of 8--12 modified peptides per unmodified tryptic peptide \[[@pone.0235263.ref010]\]. Filters were employed to isolate the DPs, to limit the number of 'background' modifications (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"} of Table B), and to limit Δ*m* to ±500 Da (for clarity of visualisation). Filtering removed 70--74% of the identified features ([S1 Fig](#pone.0235263.s001){ref-type="supplementary-material"}).

Visualisation of Δ*m* distributions {#sec012}
-----------------------------------

The filtered Δ*m* values were visualised in two ways: firstly by mapping DPs to segments of the protein sequence, and secondly using a frequency histogram \[[@pone.0235263.ref003], [@pone.0235263.ref025]\]. These modes of visualisation, both achieved using [S1 Script](#pone.0235263.s016){ref-type="supplementary-material"}, revealed a diversity of putative modifications in NEM-treated BSA ([Fig 1A and 1B](#pone.0235263.g001){ref-type="fig"}). Visualisations of putative modifications to porcine trypsin, also detected in analyses of NEM-treated BSA, demonstrated the flexibility of [S1 Script](#pone.0235263.s016){ref-type="supplementary-material"} ([S2 Fig](#pone.0235263.s002){ref-type="supplementary-material"}).

![Localisation plots and mass-shift (Δ*m*) frequency histograms for dependent peptides (DPs) of *N*-ethylmaleimide-treated bovine serum albumin.\
In the localisation plots (left-hand panels), the protein sequence is represented as a dashed line that becomes solid in regions for which peptides were observed. X-axis values refer to positions in the protein sequence (position 1 = N-terminal amino acid residue). Each DP is represented as a rectangle whose height is proportional to Δ*m*, and whose grey border is partially transparent. The Δ*m* values are summarised in frequency histograms (right-hand panels). The DPs were unenriched (A, B), enriched using [S2 Script](#pone.0235263.s017){ref-type="supplementary-material"} (C, D) or enriched using [S3 Script](#pone.0235263.s018){ref-type="supplementary-material"} (E, F).](pone.0235263.g001){#pone.0235263.g001}

Δ*m* frequency histograms were used to investigate whether modifications in NEM-treated and untreated BSA were the same. Histograms for the two samples were similar (nearly as similar, or more similar, than histograms for analytical replicates; see [S3 Fig](#pone.0235263.s003){ref-type="supplementary-material"}). This suggested that the samples had many modifications in common. In order to selectively visualise the NEM-derived modifications, we investigated ways of enriching DPs. We started with a method ([S2 Script](#pone.0235263.s017){ref-type="supplementary-material"}) that subtracts the DPs observed in an analysis of untreated protein from those observed in an analysis of treated protein ([Fig 1C and 1D](#pone.0235263.g001){ref-type="fig"}). For this purpose, DPs were regarded as simple combinations of sequence and Δ*m* (in principle, retention time could also be used, but this was not attempted here). We then took the enrichment idea a stage further ([S3 Script](#pone.0235263.s018){ref-type="supplementary-material"}) by looking for DPs that were 'constantly conjoined' with NEM treatment (i.e., observed in both analyses of NEM-treated BSA, but in neither analysis of untreated BSA). Enrichment was quantified as an increase in the percentage of DPs having either of two putative NEM-derived groups: intact NESyl (Δ*m* ± tolerance = +125.05 ± 0.01 Da) or hydrolysed NESyl (Δ*m* ± tolerance = +143.06 ± 0.01 Da). Both modifications were observed for NEM-treated BSA (8.7% of the DPs from analysis 1, [Fig 1B](#pone.0235263.g001){ref-type="fig"}) and neither was observed for untreated BSA. [S2 Script](#pone.0235263.s017){ref-type="supplementary-material"} effected 2.3-fold enrichment of DPs from analysis 1 of NEM-treated BSA ([Fig 1D](#pone.0235263.g001){ref-type="fig"}). [S3 Script](#pone.0235263.s018){ref-type="supplementary-material"} effected 6.0-fold enrichment of these same DPs, but its greater stringency led to the exclusion of eleven relevant DPs ([Fig 1F](#pone.0235263.g001){ref-type="fig"}). The results suggest that our scripts should be able to enrich DPs even when the modifications of interest are unknown. In other words, the scripts might be able to discover novel modifications and attribute them to a given reagent or condition.

Visualisation of expected modifications {#sec013}
---------------------------------------

As well as surveying the diversity of modifications, we were also interested in visualising the distributions of specific hypothesised modifications. For this purpose, we developed a method that maps 'constantly conjoined' DPs to the protein sequence and highlights their probable sites of modification ([S4 Script](#pone.0235263.s019){ref-type="supplementary-material"}). A sliding window is used as before, but in [S4 Script](#pone.0235263.s019){ref-type="supplementary-material"} its role is to direct the entry of values into matrices. Each DP is 'etched' (as a line of ones) into a blank matrix, and the localisation probabilities for that DP's modification are deposited in a corresponding zero matrix (localisation probability is a computed measure of the likelihood of a modification occurring at a given site \[[@pone.0235263.ref011], [@pone.0235263.ref012]\]). The two matrices are subsequently converted to images (R function *image* \[[@pone.0235263.ref026]\]) and merged. [Fig 2](#pone.0235263.g002){ref-type="fig"} is a formatted version of one of the resulting graphics, showing the distribution of putative hydrolysed NESyl groups. [S4 Fig](#pone.0235263.s004){ref-type="supplementary-material"} is an example of an unformatted graphic, showing the distribution of putative intact NESyl groups. Note how some of the DPs in [Fig 2](#pone.0235263.g002){ref-type="fig"} occur as pairs of putative diastereoisomers \[[@pone.0235263.ref043]\] (i.e., modified peptides with identical *m*/*z* values and fragmentation patterns but different retention times).

![Localisation plot for putative hydrolysed *N*-ethylsuccinimidyl groups in *N*-ethylmaleimide-treated bovine serum albumin (Δ*m* ± tolerance = +143.06 ± 0.01 Da).\
The protein sequence is represented as a dashed line that becomes solid in regions for which peptides were observed. X-axis values refer to positions in the protein sequence (position 1 = N-terminal amino acid residue). Dependent peptides are represented as coloured strips with shading to indicate the localisation probability (darker = more probable). Any site with a non-zero probability is annotated. One dependent peptide (amino acid residues 336--347, probably modified at Arg-336 or His-337) does not appear because the relevant matrices were full.](pone.0235263.g002){#pone.0235263.g002}

Using the hydrolysed NESyl group as an example, we examined whether the putative modifications had been localised to plausible sites. In 23 of 34 DPs with putative hydrolysed NESyl groups (68%), the highest localisation probability had been assigned to a cysteine, histidine or lysine residue ([S1 Table](#pone.0235263.s021){ref-type="supplementary-material"}). In cases where the same probability had been assigned to multiple sites, we used a system of prioritisation to narrow down the possibilities (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"} for details). Six of the 23 plausible localisations were confirmed by a variable-modification search ([S1 Table](#pone.0235263.s021){ref-type="supplementary-material"}). In all six cases, the modification could be localised to a histidine or lysine residue. Modifications to cysteine residues, which represent a special case, are discussed below. A seventh, less plausible localisation (to Asp-13) was also confirmed by the variable-modification search ([S1 Table](#pone.0235263.s021){ref-type="supplementary-material"}).

In order to discover the DPs with modified cysteine residues, we had to account for the fact that the corresponding residues in the base peptides would also be modified (*S*-carbamidomethylated). Subtracting the Δ*m* for carbamidomethylation gave new values for NESyl (+68.03 Da) and hydrolysed NESyl (+86.04 Da), both of which we recognised from the Δ*m* frequency histograms ([Fig 1](#pone.0235263.g001){ref-type="fig"}). Surprisingly, neither modification was localised to Cys-34 ([S5](#pone.0235263.s005){ref-type="supplementary-material"} and [S6](#pone.0235263.s006){ref-type="supplementary-material"} Figs), and no modified cysteine residues were confirmed by the variable-modification search. Seeking to understand the apparent absence of modifications to Cys-34, we turned to a group of unexplained DPs (Δ*m* = −25.03 Da; [Fig 1F](#pone.0235263.g001){ref-type="fig"}), which we speculated might contain oxidised cysteine residues (cysteinesulfinic acid). The modification was found to have been localised to Cys-34 in some DPs, but none that were 'constantly conjoined' with NEM treatment ([S7 Fig](#pone.0235263.s007){ref-type="supplementary-material"}). The ambiguous results for Cys-34 are possibly a consequence of modifications at this site having decomposed prior to or during analysis. We did see some evidence of modification to cysteine residues other than Cys-34 ([S1 Table](#pone.0235263.s021){ref-type="supplementary-material"}, [S5](#pone.0235263.s005){ref-type="supplementary-material"}--[S7](#pone.0235263.s007){ref-type="supplementary-material"} Figs), and this was unexpected because these residues are normally disulfide-bonded to other cysteine residues \[[@pone.0235263.ref031]\]. It is possible that modifications to cysteine residues other than Cys-34 occurred when DTT was added to scavenge unreacted NEM. It is also possible that some of the other modifications observed in the study occurred following this addition of DTT.

The above results highlight the fact that observed Δ*m* values do not always correspond to real chemical transformations, and cannot always be interpreted directly. Direct interpretation is permitted if the DP is singly-modified and the base peptide is truly unmodified, and likewise if the DP and base peptide contain modifications that 'cancel out' (e.g., cysteine *S*-carbamidomethylation). However, if the base peptide contains modifications not found in the DP, or if the base peptide and DP contain different modifications at the same site, then interpretation will be less straightforward. Problems of this nature could be avoided by omitting modifications from the database search, but this would of course restrict the overall number of identifications.

Validation of tools using public data {#sec014}
-------------------------------------

We explored the scripts' generality by applying them to analyses of public data. We hypothesised that a combination of DP searching and visualisation would reveal the same adducts as other authors had found by variable-modification database searching. We expected to observe these adducts via targeted visualisation (e.g., using [S4 Script](#pone.0235263.s019){ref-type="supplementary-material"}). We also predicted that they would be evident from an untargeted survey (e.g., using [S3 Script](#pone.0235263.s018){ref-type="supplementary-material"}).

First, we analysed data from a study by Piroli et al. \[[@pone.0235263.ref027]\]. In this work, cultured cells (rat astrocytes) were exposed to the drug dimethyl fumarate. The authors collected proteins from the exposed cells, resolved them on gels, and then subjected individual protein bands to reduction, alkylation (4-vinylpyridine), digestion (trypsin) and analysis. In one of the protein bands, the authors detected a monomethyl fumarate adduct of cofilin-1 and localised the modification to a cysteine residue (Cys-139). Using the methods developed for the analysis of NEM-treated BSA, we performed an independent analysis of Piroli and coauthors' cofilin-1 data. [S1 Script](#pone.0235263.s016){ref-type="supplementary-material"} was used to survey Δ*m* values, and an additional script was developed for mapping the expected Δ*m* ([S5 Script](#pone.0235263.s020){ref-type="supplementary-material"}, an analogue of [S4 Script](#pone.0235263.s019){ref-type="supplementary-material"} that works with single allPeptides.txt files). [S1 Script](#pone.0235263.s016){ref-type="supplementary-material"} did not highlight the expected nominal Δ*m* (+25 Da; [S8 Fig](#pone.0235263.s008){ref-type="supplementary-material"}), which is perhaps understandable given this script's inability to enrich DPs. The overall sparsity of [S8 Fig](#pone.0235263.s008){ref-type="supplementary-material"} could reflect a real lack of modifications in the rat cofilin-1, or alternatively it could reflect qualities of the sample and/or data. [S5 Script](#pone.0235263.s020){ref-type="supplementary-material"} revealed that the expected Δ*m* (+24.97 ± 0.01 Da) was present in one DP, and that it had been localised to the correct cysteine residue ([S9 Fig](#pone.0235263.s009){ref-type="supplementary-material"}). The Δ*m* itself is also evidence of correct localisation, since this is the difference in mass with respect to a pyridylethylated base peptide. The discrepancy in the site numbers (138 versus 139) arose probably because we used the sequence of mature rat cofilin-1 (no N-terminal methionine residue) whereas Piroli et al. used the sequence of the full-length protein (we used mature sequences where possible to ensure that N-terminal peptides could be found by Andromeda).

Further data were from a study by Salomón et al. \[[@pone.0235263.ref028]\]. In this work, the reactivity of human blood proteins towards a metabolite, 3-hydroxy-2,5-hexanedione, was explored using an alkyne-functionalised probe ('alk-3-HHD'). The authors prepared plasma from probe-treated blood and collected the plasma proteins. The proteins were reduced, alkylated (iodoacetamide) and digested (trypsin), and the resulting peptides were chemically enriched for alk-3-HHD adducts. The authors detected two different types of modification ('HTO' and 'HDMP', both specific to lysine residues) among six polypeptides (apolipoprotein A-I, haemoglobin β- and δ-chains, serotransferrin, serum albumin, and transthyretin). In total, the authors detected 18 unique sites of modification among 22 analytes. Again, we applied methods that had been developed for the BSA adducts. Salomón and coauthors' dataset included replicates and a control, permitting the use of [S3](#pone.0235263.s018){ref-type="supplementary-material"} and [S4 Scripts](#pone.0235263.s019){ref-type="supplementary-material"}. To maximise contrast, we used data for the highest concentration of alk-3-HHD. [S3 Script](#pone.0235263.s018){ref-type="supplementary-material"} revealed multiple 'constantly conjoined' DPs of each of the six aforementioned polypeptides, but did not highlight any of the expected Δ*m* values ([Fig 3A and 3B](#pone.0235263.g003){ref-type="fig"}; [S10](#pone.0235263.s010){ref-type="supplementary-material"}--[S14](#pone.0235263.s014){ref-type="supplementary-material"} Figs). Six DPs mapped to both of the haemoglobin chains, and therefore could not be localised unambiguously. [S4 Script](#pone.0235263.s019){ref-type="supplementary-material"} was used to map HTO- and HDMP-type modifications (with or without sulfonation \[[@pone.0235263.ref028]\]) to the sequences of the polypeptides. In total, 14 DPs with putative alk-3-HHD-derived modifications were detected (11 unique combinations of sequence and modification) ([S2 Table](#pone.0235263.s022){ref-type="supplementary-material"}). In each of the DPs, a lysine residue was either the site with the highest localisation probability, or was one of multiple such sites. Most of the DPs (93%) were of either haemoglobin β-chain ([Fig 3C](#pone.0235263.g003){ref-type="fig"}) or serum albumin ([S15 Fig](#pone.0235263.s015){ref-type="supplementary-material"}). Of the 22 analytes reported by Salomón et al., we detected six (27%) as DPs. Of the 18 expected sites of modification, we observed seven (39%). It is perhaps unsurprising that some of the expected DPs were not detected, since the chemical enrichment performed by Salomón et al. had the potential to remove their corresponding base peptides (an effect alluded to by Tyanova et al. in their protocol \[[@pone.0235263.ref011]\]). Indeed, for seven of the 22 expected analytes (32%), the absence of a required base peptide was sufficient to explain the absence of the DP.

![Visualisation of dependent peptides of human haemoglobin β-chain using public data from the study by Salomón et al. \[[@pone.0235263.ref028]\].\
(A) Dependent peptide localisation plot. (B) Mass-shift (Δ*m*) frequency histogram. (C) Localisation plot for putative sulfonated 'HDMP'-type modifications (Δ*m* ± tolerance = +390.10 ± 0.01 Da) \[[@pone.0235263.ref028]\]. Six of 106 dependent peptides also mapped to the sequence of haemoglobin δ-chain ([S11 Fig](#pone.0235263.s011){ref-type="supplementary-material"}). Base peptide VLGAFSDGLAHLDNLKGTFATLSELHCDK went undetected in analyses of untreated proteins and therefore does not appear (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"} of Table C).](pone.0235263.g003){#pone.0235263.g003}

Scope for extending the present study {#sec015}
-------------------------------------

There is scope beyond the present study for developing and integrating the visualisation tools. As R scripts, they are highly amenable to modification, and could be adapted for more specialised purposes. The filters and the Δ*m* tolerance could made more stringent or permissive as required. The plots could be customised by changing the colour scheme or narrowing the limits of the Δ*m* axes. Another idea would be to rotate the histogram so as to align its Δ*m* axis with that of the DP localisation plot.

One area in which there is significant scope for development is annotation. Currently, the scripts highlight mass shifts but do not attempt to identify them. Some identifications are already made by MaxQuant, and these could be easily transferred onto the plots. Further identifications could be made via public protein-modification databases such as Unimod \[[@pone.0235263.ref037]\] and RESID \[[@pone.0235263.ref044]\]. These databases contain calculated Δ*m* values via which observed Δ*m* values could be linked to modifications' identities. Identities could be added to the plots or visualised separately (e.g., a word-cloud of modifications' names). Another idea would be to highlight particular features of the protein sequence, such as nucleophilic amino acid residues. This could be done using lines, symbols or text.

Currently, each script visualises results for a single protein ([S1](#pone.0235263.s016){ref-type="supplementary-material"}--[S3 Scripts](#pone.0235263.s018){ref-type="supplementary-material"}) or combination of protein and Δ*m* ([S4](#pone.0235263.s019){ref-type="supplementary-material"} and [S5](#pone.0235263.s020){ref-type="supplementary-material"} Scripts). One way of extending the approach would be to iterate scripts so that they cycle through lists of proteins and/or Δ*m* values (in fact, we prepared certain groups of figures in this way). In theory, this could be done in a 'data-dependent' fashion by extracting the lists directly from allPeptides.txt. If this were attempted, each graphic (e.g., \*.svg file) would have to be stamped with the protein identifier and/or Δ*m* value.

[S2](#pone.0235263.s017){ref-type="supplementary-material"}, [S3](#pone.0235263.s018){ref-type="supplementary-material"} and [S4](#pone.0235263.s019){ref-type="supplementary-material"} Scripts are able to enrich DPs for modifications that are unique to a test sample. The modes of enrichment employed by the scripts are simple but should work well for many *in vitro* modifications (especially modifications not found *in vivo*). The visualisation of *in vivo* modifications would be an impactful next step, but one that might require a more quantitative approach: it would be helpful to visualise differences in abundance in addition to the simple difference between presence and absence.

Finally, there is scope for combining the scripts in an R package \[[@pone.0235263.ref045]\]. This would promote their usability beyond the present study.

Summary {#sec016}
-------

We have developed and tested a set of analytical tools with which to interpret the results of a DP search. The tools visualise putative modifications (Δ*m* values) for a protein of interest (either an isolated protein or a component of a proteome). Some of the tools are able to enrich DPs for modifications that are unique to a test sample. We envisaged that an untargeted survey of DPs (using [S1](#pone.0235263.s016){ref-type="supplementary-material"}--[S3 Scripts](#pone.0235263.s018){ref-type="supplementary-material"}) might generate hypotheses that could then be tested via targeted visualisation (using [S4](#pone.0235263.s019){ref-type="supplementary-material"} and [S5](#pone.0235263.s020){ref-type="supplementary-material"} Scripts). This approach helped us to achieve our aim of rationalising DP search results for NEM-treated BSA. Expected modifications were found, and the majority of these were localised to chemically plausible sites. In formal tests involving public data, a number of expected modifications were detected and correctly localised (although here the methods for surveying Δ*m* values proved less helpful than they had for the BSA study). Analyses of cysteine-specific modifications led us to consider the effect of fixed and variable modifications on Δ*m*; and analyses of data for chemically enriched peptides led us to consider the potential of chemical enrichment to limit DP searches. We conclude (i) that the tools can summarise DP search results accurately and informatively, and (ii) that DP searching can be useful for characterising *in vitro* modified proteins.

Supporting information {#sec017}
======================

###### Numbers of features identified in analyses of NEM-treated and untreated BSA.

After filtering, the numbers of dependent peptides (DPs) were all similar (no two counts differed by more than 5%). 'Conjoined' DPs were those detected in analysis 1 of NEM-treated BSA and not detected in analysis 1 of untreated BSA. 'Constant' DPs were those detected in both analyses of NEM-treated BSA. 'Constantly conjoined' DPs were those detected in both analyses of NEM-treated BSA and not detected in either analysis of untreated BSA.

(TIF)

###### 

Click here for additional data file.

###### Localisation plot and mass-shift frequency histogram for dependent peptides of porcine trypsin.

MaxQuant identified three putative deamidations and a putative methylation. Two of the deamidations were localised to asparagine residues.

(TIF)

###### 

Click here for additional data file.

###### Similarity of mass-shift frequency histograms.

Three pairwise comparisons are shown: treated/treated, untreated/untreated and treated/untreated. The treated/untreated pair shown is the least similar of four possible combinations. *ρ* = Spearman correlation coefficient.

(TIF)

###### 

Click here for additional data file.

###### Probability localisation plot for putative intact NESyl groups in NEM-treated BSA (Δ*m* ± tolerance = +125.05 ± 0.01 Da).

X-axis values refer to positions in the protein sequence.

(TIF)

###### 

Click here for additional data file.

###### Probability localisation plot for additional intact NESyl groups in NEM-treated BSA (Δ*m* ± tolerance = +68.03 ± 0.01 Da).

X-axis values refer to positions in the protein sequence.

(TIF)

###### 

Click here for additional data file.

###### Probability localisation plot for additional putative hydrolysed NESyl groups in NEM-treated BSA (Δ*m* ± tolerance = +86.04 ± 0.01 Da).

X-axis values refer to positions in the protein sequence.

(TIF)

###### 

Click here for additional data file.

###### Probability localisation plot for putative oxidations in NEM-treated BSA (Δ*m* ± tolerance = −25.03 ± 0.01 Da).

X-axis values refer to positions in the protein sequence.

(TIF)

###### 

Click here for additional data file.

###### Localisation plot and mass-shift frequency histogram for dependent peptides of cofilin-1 from dimethyl-fumarate-treated rat astrocytes \[[@pone.0235263.ref027]\].

The nominal Δ*m* of +105 Da is consistent with pyridylethylation of non-cysteine residues.

(TIF)

###### 

Click here for additional data file.

###### Probability localisation plot for 1-carboxy-2-methylcarboxyethyl groups in cofilin-1 from dimethyl-fumarate-treated rat astrocytes \[[@pone.0235263.ref027]\] (Δ*m* ± tolerance = +24.97 ± 0.01 Da).

X-axis values refer to positions in the protein sequence.

(TIF)

###### 

Click here for additional data file.

###### Localisation plot and mass-shift frequency histogram for dependent peptides of apolipoprotein A-I from alk-3-HHD-treated human blood \[[@pone.0235263.ref028]\].

(TIF)

###### 

Click here for additional data file.

###### Localisation plot and mass-shift frequency histogram for dependent peptides of haemoglobin δ-chain from alk-3-HHD-treated human blood \[[@pone.0235263.ref028]\].

All six dependent peptides also mapped to the sequence of haemoglobin β-chain ([Fig 3](#pone.0235263.g003){ref-type="fig"}).

(TIF)

###### 

Click here for additional data file.

###### Localisation plot and mass-shift frequency histogram for dependent peptides of serotransferrin from alk-3-HHD-treated human blood \[[@pone.0235263.ref028]\].

(TIF)

###### 

Click here for additional data file.

###### Localisation plot and mass-shift frequency histogram for dependent peptides of serum albumin from alk-3-HHD-treated human blood \[[@pone.0235263.ref028]\].

(TIF)

###### 

Click here for additional data file.

###### Localisation plot and mass-shift frequency histogram for dependent peptides of transthyretin from alk-3-HHD-treated human blood \[[@pone.0235263.ref028]\].

(TIF)

###### 

Click here for additional data file.

###### Probability localisation plot for putative sulfonated HDMP-type modifications in serum albumin from alk-3-HHD-treated human blood \[[@pone.0235263.ref028]\] (Δ*m* ± tolerance = +390.10 ± 0.01 Da).

X-axis values refer to positions in the protein sequence.

(TIF)

###### 

Click here for additional data file.

###### An R script that filters dependent peptides and generates a dependent-peptide localisation plot and a mass-shift frequency histogram.

\(R\)

###### 

Click here for additional data file.

###### An R script that filters dependent peptides, enriches them on the basis of 'conjunction' and generates a dependent-peptide localisation plot and a mass-shift frequency histogram.

\(R\)

###### 

Click here for additional data file.

###### An R script that filters dependent peptides, enriches them on the basis of 'constant conjunction' and generates a dependent-peptide localisation plot and a mass-shift frequency histogram.

\(R\)

###### 

Click here for additional data file.

###### An R script that isolates dependent peptides with a specified mass shift, enriches them on the basis of 'constant conjunction' and generates a probability localisation plot.

\(R\)

###### 

Click here for additional data file.

###### An R script that isolates dependent peptides with a specified mass shift and generates a probability localisation plot.

\(R\)

###### 

Click here for additional data file.

###### Dependent peptides and matching variable-modification search results.

Localisation probabilities for hydrolysed NESyl groups are given in parentheses after the respective amino acid symbols. Potential sites of modification are underlined, with the most plausible sites in boldface (see [S1 Text](#pone.0235263.s023){ref-type="supplementary-material"}). Dependent peptides were allowed to have either of two mass shifts: +86.04 ± 0.01 Da or +143.06 ± 0.01 Da (see 'Results and discussion').

(XLSX)

###### 

Click here for additional data file.

###### Dependent peptides with putative alk-3-HHD-derived modifications.

Dependent peptides containing HDMP-/HTO-type modifications were identified using [S4 Script](#pone.0235263.s019){ref-type="supplementary-material"}. All modifications were detected as sulfonyl derivatives, and all could be localised to lysine residues. DPs were matched to Salomón and coauthors' search results \[[@pone.0235263.ref028]\] ('+' = match) by sequence, site of modification and modification type ('Expected analyte'), or by protein site only ('Expected site'). Two site numbers are given: the number used for the matching (first number); and the equivalent number for the mature protein (second number, in parentheses).

(XLSX)

###### 

Click here for additional data file.

###### Supplementary methods.

Chemicals; Preparation of BSA adducts; Sample preparation for mass spectrometry; Nano liquid chromatography and mass spectrometry; Enumeration of tryptic peptides; Calculation of maximum peptide mass; Contaminant databases; Comparison of dependent-peptide and variable-modification search results; Figure preparation; References; Table A (Gradient elution timetable); Table B (Criteria used to filter dependent-peptide search results); Table C (Explanatory notes to accompany scripts).

(PDF)

###### 

Click here for additional data file.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

As shown by the numerous questions of the reviewers the manuscript is currently not clear enough on the actual use of the visualisation tools that are proposed. The lack of details in the case studies and the subsequent confusion in understanding the visualisation is a concern. The revised version should not only include more detailed information but also refer to more of the existing resources describing PTMs.

We would appreciate receiving your revised manuscript by April 27, 2020. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.
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Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.
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Frederique Lisacek

Academic Editor
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When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript by Preston et al. provides several visualization scripts for the interpretation of dependent peptide (DP) search results in MaxQuant. Such post-analysis tools are currently lacking (at least I couldn\'t find any) and thus can be of a general interest to those performing MaxQuant DP searches.

Preston et al. provide original research results and describe new DP visualization tools that were tested on a generated NEM-treated BSA model dataset, as well as two public datasets that introduced in vitro protein modifications. Analyses are in general well-conducted and the applied methodology is well elaborated. Importantly, DP search results were adequately filtered as outlined in Table B in the supplementary text file. Also FDR statistics and protein localisations are provided by the popular, statistically sound MaxQuant suite. In case of the analysis of the NEM-treated BSA dataset and the public human blood proteome dataset, I believe the conclusion to follow after correct interpretation of the results. The raw proteomics data, peak lists and MaxQuant search results of the BSA dataset are provided in a public repository as required.

I have perhaps one major consideration where I am doubtful on the conclusion;

\- In the presented results of the rat public dataset (results Fig. S8-S9), the frequency of these Δm is dramatically low if comparing to frequencies observed in the BSA model set. The modification of interest (+24.9606 Da) was identified solely once as a DP. So, the localization in Fig S9 would be then assumed on a single DP? Although given the a priori knowledge of this modification, this was considered to be a valid confirmation. However, it would most likely never be identified or distinguished without this knowledge a priori. I am unsure whether I am interpreting this correctly, or this is due to the quality of the data?

I have two further considerations that are I believe not critical points regarding criteria for publication but could improve the quality of the work:

1\) A major aim of the manuscript is to promote the visualization tools and that proteomic researchers can apply these scripts in a user-friendly manner to interpret novel or anticipated modifications. Currently, there is a reference to an empty github user page (<https://github.com/preston-gw/>) where further development would be presented. Perhaps a good alternative to stimulate further usage is to gather these R scripts in a single R package that can be installed and loaded with a name that could be cited (instead of \'the visualization tools\'). For instance, such R algorithms are often accessible via R/Bioconductor. Also scripts could be implemented as functions with an intuitive name, as currently (although well-elaborated) there is quite some complexity with five different script termed Script I to Script V. I don\'t believe this to be a critical point if viewing criteria for publication, although it could be I think greatly beneficial for future usage.

2\) Overall the manuscript is focused on in vitro modifications, as stated in the title. However, the methodology could easily be applied on biological, in vivo modifications. For instance, it would be interesting to compare dependent peptide searches with or without a certain cellular stress or comparing wild-type versus mutants in PTM modifying enzymes. Certain scripts such as Script III would definitely be too stringent, but overall this is perhaps a missed chance to broaden up towards analysis of in vivo modifications that are of general interest to the proteomics community.

Besides these comments I noted several rather minor things during reading:

Abstract:

\- Line 31-32: 'To facilitate interpretation of the search results, of which there were hundreds, we \...' , reads very vague. Are we talking here about identified dependent peptides or all identifications?

\- Lines 34-36: after stating that public rat and human proteome data was searched, 19 expected modifications sites were anticipated. I'm confused, are we expecting these modifications in whole species proteomes or on the BSA model dataset that was generated? If on the model dataset, these anticipated modification sites would be best described before mentioning the whole proteome public datasets.

Introduction

\- Line 49-50: I think an obvious reason being that specifying too many variable modifications will result in a search database expansion eventually having a negative effect on obtained peptide identifications at a certain FDR threshold.

\- Line 64-65: 'Mordret et al. recently carried out a validation of the function using phosphoproteome \[12\]'. I was initially confused as the cited reference focuses on amino acid substitutions. However they did assess the performance of the DP search using a model phosphorylation dataset. The sentence have to be rephrased to make f this more clear, it is in fact a very relevant work where the DP reliability was evaluated.

\- Line 69-71: I guess an important incentive is that no such visualization tool is yet available for automated interpretation and visualization for MaxQuant dependent-peptide results?

Methods

\- Line 94-95: The contaminant list from MaxQuant was edited to remove irrelevant or interfering sequences? I did not find any more information on this part.

-Lines 198: Script II removes DPs (peptide and Δm) identified in non-treated sample from the NEM-treated sample. Hence, in theory negative values can occur, but I guess these are not plotted or can we consider under-representation? Taken together, I feel that both Script II applies a rather simplistic rule to look at enrichment by simply subtracting DP peptides. Would it be more adequate considering for instance a more \'relative/normalized\' approach, e.g. perhaps by considering a ratio of treated versus untreated or something similar?

FIGURES

\- Fig S1: What is analysis 1 and 2, might be better termed as replicate 1 and 2?

\- Fig S2: Is this indicative of any nucleophilic residue in trypsin that is known to be modified? Not specified in legend.

\- Fig. 1:

o Irrespective of the frequency of certain Δm at a single localization, the rectangles would appear similar. Ideally, would it be possible to tune the transparency or a color gradient according to the frequency of Δm's? Another way would be to look in certain mass bins of the Δm frequency plot and deduce whether any protein localization are overrepresented.

o Would it be worthwhile to indicate nucleophilic amino acids on the x-axis or with vertical lines if not making this too complex?

Overall, I believe this work to fulfill the publication criteria, though definitely further modifications could improve the manuscript.

Reviewer \#2: The manuscript describes a tool containing several R scripts that aim to facilitate the analysis of data coming from a dependent peptide database search, looking for modified versions of identified proteins. The focus is on proper visualizations that give an overview about the found peptides and modifications.

The manuscript is well written but I still miss several items and am also not yet convinced about how much the visualization may help an interested user.

Major comments

1\) The 3 presented figure types are quite simple and should be enhanced.

Taking figure 3, then the figure 3A could have thinner lines and maybe use transparency to further distinguish otherwise overlapping squares.

Also, as figures 3A and 3B are complementary, why not rotating the figure 3B 90 degrees and show it along with the y-axis of figure 3A?

I do not see that Figure 3C contains information about the mass shifts and thus it is limited in its usage, particularly for researchers that aim to understand a particular modification.

The use of colors is limited to some shades of blue and red lines. Given that we have the year 2020, I suggest to take advantage of a larger color palette.

How about zooming into regions of interest in a protein? Does the script allow to look into a region within the full protein sequence? And can one visualize a subset of the modifications, e.g. by specifying a smaller mass range?

When having a larger dataset with many proteins, is there any visualization of the full set of proteins, helping the researcher to find out which would be the proteins with particularly interesting patterns?

2\) I miss the aim of the study. Which are scenarios where the tools will be of help? Does it target the investigation of samples containing one protein or simple mixtures, or also complex samples with thousands of proteins? If the latter was the case, what would the analysis procedure be?

3\) What about the scripts\' potential to visualize in vivo PTMs? This would be very interesting to a much broader readership. Another rather simple enhancement would be to look into the identify of the different mass shifts. They could be compared to UniMod/ResID databases and the putative names of the modifications could be extracted, and then for instance shown as word cloud.

Minor comments

\- The introduction would benefit from a short comparison of open database search and dependent search, including their challenges and advantages

\- I am missing a short description about the flexibility of the scripts to vary the visualizations and/or to extend them to include other information

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to reviewers

Academic Editor's comments

As shown by the numerous questions of the reviewers the manuscript is currently not clear enough on the actual use of the visualisation tools that are proposed. The lack of details in the case studies and the subsequent confusion in understanding the visualisation is a concern. The revised version should not only include more detailed information but also refer to more of the existing resources describing PTMs.

Response: We thank the Academic Editor and the reviewers for their constructive comments. To address concerns about the use of the tools, we have revised the Introduction (final paragraph) and the Results and Discussion ('Validation of tools using public data', 'Scope for extending the present study', 'Summary'). Specifically we have tried to better convey the idea that some scripts are primarily hypothesis-generating while others are hypothesis-testing. To address the lack of detail in the case studies, we have included extra information in Materials and Methods ('Public data') and Results and Discussion ('Validation of tools using public data' and 'Summary'). We have also included a more detailed discussion of the effects of 'fixed' and 'variable' modifications on observed ∆m values ('Visualisation of expected modifications' in Results and Discussion).

We have cited publications describing the Unimod and RESID databases ('Scope for extending the present study' in Results and Discussion) and have mentioned that Unimod was the source of mass data for some of our calculations ('Mass calculations' in Materials and Methods).

In addition, we have:

• clarified certain aspects of script development and usage (Materials and Methods);

• clarified certain aspects of figure preparation ('Figure preparation' in S1 Text);

• reworded a few phrases to make them clearer and more concise (e.g., in the Abstract);

• added detail to figure captions where necessary;

• cited an additional publication (ref. 21) in which dependent-peptide search results have been reported;

• pointed out that the results for haemoglobin δ-chain overlapped with those for haemoglobin β-chain (apologies -- this did not come to light until the revision stage).

Further changes relating to reviewers' comments are detailed below.

First reviewer's comments

I have perhaps one major consideration where I am doubtful on the conclusion; - In the presented results of the rat public dataset (results Fig. S8-S9), the frequency of these Δm is dramatically low if comparing to frequencies observed in the BSA model set. The modification of interest (+24.9606 Da) was identified solely once as a DP. So, the localization in Fig S9 would be then assumed on a single DP? Although given the a priori knowledge of this modification, this was considered to be a valid confirmation. However, it would most likely never be identified or distinguished without this knowledge a priori. I am unsure whether I am interpreting this correctly, or this is due to the quality of the data?

Response: We acknowledge that the ∆m in question is not prominent in Figure S8, and therefore would not have been picked out using the simple survey approach. Also, the interpretation of this ∆m is not straightforward (it is actually the shift with respect to a pyridylethylated base peptide). Consider however that Figure S8 was generated using Script I, which cannot perform enrichment. If we been able to use Script II/III, then the ∆m of interest might have been more obvious. Still, Figure S8 does have some interesting features: the ∆m of +105 Da, for example, is likely due to pyridylethylation of non-cysteine residues. The sparsity of Figures S8 and S9 could reflect a real lack of modifications in the rat cofilin-1, or it could reflect a property of the sample or the quality of the data. Our finding of a single dependent peptide is actually consistent with Piroli and coauthors' finding of a single peptide-spectrum match (see Table I in ref. 27). In the revised manuscript it has been made clear that Script I did not by itself identify the modification of interest. It has also been pointed out that Script III did not by itself identify expected modifications in plasma proteins. A related comment has been added to the 'Summary' section of Results and Discussion. A note regarding the 105-Da shift has been added to the caption of Figure S8.

A major aim of the manuscript is to promote the visualization tools and that proteomic researchers can apply these scripts in a user-friendly manner to interpret novel or anticipated modifications. Currently, there is a reference to an empty github user page (<https://github.com/preston-gw/>) where further development would be presented. Perhaps a good alternative to stimulate further usage is to gather these R scripts in a single R package that can be installed and loaded with a name that could be cited (instead of \'the visualization tools\'). For instance, such R algorithms are often accessible via R/Bioconductor. Also scripts could be implemented as functions with an intuitive name, as currently (although well-elaborated) there is quite some complexity with five different script termed Script I to Script V. I don\'t believe this to be a critical point if viewing criteria for publication, although it could be I think greatly beneficial for future usage.

Response: We agree that combining the scripts in a package would promote their usability. Currently we do not have experience of preparing R packages (however we acknowledge that this could be gained without too much difficulty). We appreciate that a package would be easier to cite than five different numbered scripts. The five-script system does however establish a clear link between results and methods, and should aid reproducibility of results. The idea of integrating the scripts has been included in a new section of Results and Discussion ('Scope for extending the present study'). A publication describing R packages and Bioconductor has been cited.

Overall the manuscript is focused on in vitro modifications, as stated in the title. However, the methodology could easily be applied on biological, in vivo modifications. For instance, it would be interesting to compare dependent peptide searches with or without a certain cellular stress or comparing wild-type versus mutants in PTM modifying enzymes. Certain scripts such as Script III would definitely be too stringent, but overall this is perhaps a missed chance to broaden up towards analysis of in vivo modifications that are of general interest to the proteomics community.

Response: We agree that tools for visualising in vivo modifications would be very useful to the proteomics community. The current scripts are probably more appropriate for looking at modifications not found in vivo. Scripts II, III and IV enrich dependent peptides for modifications that are unique to a test sample; they test for presence versus absence. For in vivo modifications, a more quantitative approach might be better. This idea has been included in the new section of Results and Discussion ('Scope for extending the present study').

Line 31-32: 'To facilitate interpretation of the search results, of which there were hundreds, we \...' , reads very vague. Are we talking here about identified dependent peptides or all identifications?

Response: Apologies -- we meant dependent peptides only. The sentence has been revised.

Lines 34-36: after stating that public rat and human proteome data was searched, 19 expected modifications sites were anticipated. I'm confused, are we expecting these modifications in whole species proteomes or on the BSA model dataset that was generated? If on the model dataset, these anticipated modification sites would be best described before mentioning the whole proteome public datasets.

Response: Apologies -- we meant expected sites in rat cofilin-1 and the human plasma proteins only. The sentence has been revised.

Line 49-50: I think an obvious reason being that specifying too many variable modifications will result in a search database expansion eventually having a negative effect on obtained peptide identifications at a certain FDR threshold.

Response: More detail has been added and a reference has been cited.

Line 64-65: 'Mordret et al. recently carried out a validation of the function using phosphoproteome \[12\]'. I was initially confused as the cited reference focuses on amino acid substitutions. However they did assess the performance of the DP search using a model phosphorylation dataset. The sentence have to be rephrased to make f this more clear, it is in fact a very relevant work where the DP reliability was evaluated.

Response: We agree that this piece of supporting evidence is actually rather important. The description of Mordret and coauthors' study has been expanded.

Line 69-71: I guess an important incentive is that no such visualization tool is yet available for automated interpretation and visualization for MaxQuant dependent-peptide results?

Response: Certainly we are not aware of any other tools that can map dependent peptides to sequences (although ∆m frequency histograms are quite common). The motivation for developing the tools has been stated in the Introduction. Also, we thought of two more references to cite: one describes MaxQuant's viewer module, which can visualise raw mass spectrometry data and Andromeda search results; the other describes the Perseus software, which can draw histograms.

Line 94-95: The contaminant list from MaxQuant was edited to remove irrelevant or interfering sequences? I did not find any more information on this part.

Response: Further details have been added to S1 Text.

Lines 198: Script II removes DPs (peptide and Δm) identified in non-treated sample from the NEM-treated sample. Hence, in theory negative values can occur, but I guess these are not plotted or can we consider under-representation? Taken together, I feel that both Script II applies a rather simplistic rule to look at enrichment by simply subtracting DP peptides. Would it be more adequate considering for instance a more \'relative/normalized\' approach, e.g. perhaps by considering a ratio of treated versus untreated or something similar?

Response: It is correct to say that the dependent peptides removed by Script II are not plotted (although one can get an idea of which ones they were by comparing Figures 1A and 1B). The negative values proposed by the reviewer would correspond to ∆m frequencies for the deleted peptides. In theory, Script II could be adapted to visualise these. We fully agree that a more quantitative approach would be helpful, particularly when dealing with in vivo modifications. The idea of quantitative comparisons has been included in the new section of Results and Discussion ('Scope for extending the present study').

Fig S1: What is analysis 1 and 2, might be better termed as replicate 1 and 2?

Response: Figures S1 and S3 have been updated. A reference to 'analytical replicates' has been made in Materials and Methods.

Fig S2: Is this indicative of any nucleophilic residue in trypsin that is known to be modified? Not specified in legend.

Response: None of these putative trypsin modifications could be attributed to a nucleophilic character of trypsin; they may all be 'background' modifications or artefacts. The main findings have summarised in the caption of Figure S2.

Fig. 1:

Irrespective of the frequency of certain Δm at a single localization, the rectangles would appear similar. Ideally, would it be possible to tune the transparency or a color gradient according to the frequency of Δm's? Another way would be to look in certain mass bins of the Δm frequency plot and deduce whether any protein localization are overrepresented.

Response: Rectangles' borders have been made partially transparent (Figures 1, 3, S2, S8 and S10-14). Scripts I-III have been updated (the transparency originates from the underlying code).

Would it be worthwhile to indicate nucleophilic amino acids on the x-axis or with vertical lines if not making this too complex?

Response: We agree that the annotation of nucleophilic residues could be very useful. We did try implementing the idea in early versions of Script IV but the resulting plots looked a bit cluttered. We also struggled to annotate disulfide bonds in a generalised way. The idea of annotating nucleophilic sites has been included in the new section ('Scope for extending the present study').

Second reviewer's comments

The 3 presented figure types are quite simple and should be enhanced. Taking figure 3, then the figure 3A could have thinner lines and maybe use transparency to further distinguish otherwise overlapping squares.

Response: We agree. The line width has been reduced (Figures 1-3, S1 and S3) and rectangles' borders have been made partially transparent (Figures 1, 3, S2, S8 and S10-14).

Also, as figures 3A and 3B are complementary, why not rotating the figure 3B 90 degrees and show it along with the y-axis of figure 3A?

Response: This is an excellent idea that had not occurred to us. Rotating a histogram is not straightforward in R, but could probably be achieved using 'barplot'. The idea has been included in the new section of Results and Discussion ('Scope for extending the present study').

I do not see that Figure 3C contains information about the mass shifts and thus it is limited in its usage, particularly for researchers that aim to understand a particular modification.

Response: Figure 3C shows the result of a targeted data analysis using Script IV; it shows how the localisations probabilities for an expected mass shift (+390.10 ± 0.01 Da) are distributed within each dependent peptide. In the case of Figure 3C, the expected shift is given in the figure caption. For traceability, Script IV could be modified to print the expected shift on the plot, or to incorporate the shift into the name of an output file. Indeed, our usual approach was to incorporate the shift into the name of an \*.svg file. The idea of stamping graphics with identifying information has been included in the new section of Results and Discussion ('Scope for extending the present study').

The use of colors is limited to some shades of blue and red lines. Given that we have the year 2020, I suggest to take advantage of a larger color palette.

Response: Adding transparency has generated some additional contrast in many of the figures, and we hope that this has gone some way to addressing the reviewer's concerns. For consistency, the red colour has been added to all dependent-peptide localisation plots. For figures such as Figure 2, the chosen colour palette gets filtered through a partially-transparent blue strip. For this reason, we preferred to keep the colour palette as simple as possible (the blues in Figure 2 are actually greys as seen through a blue filter). The idea of a broader colour palette has been included in the new section of Results and Discussion ('Scope for extending the present study').

How about zooming into regions of interest in a protein? Does the script allow to look into a region within the full protein sequence? And can one visualize a subset of the modifications, e.g. by specifying a smaller mass range?

Response: To alter the dimensions of the graphics, users could either modify the underlying code or manually stretch the graphics window. Currently, the mass ranges are 1000 Da for the untargeted visualisations (e.g., Script III/Figure 3A) and 0.02 Da for the targeted visualisations (e.g., Script IV/Figure 3C). For targeted visualisations, the tolerance can be increased or decreased as required. Ways of adjusting the scripts have been mentioned in the new section of Results and Discussion ('Scope for extending the present study').

When having a larger dataset with many proteins, is there any visualization of the full set of proteins, helping the researcher to find out which would be the proteins with particularly interesting patterns?

Response: Scripts I-III generate one graphic per protein. Scripts IV and V generate one graphic per combination of protein and mass shift. In theory, these scripts could be modified to enumerate proteins, retrieve relevant protein sequences and generate batches of graphics. In fact, we did implement this idea albeit on a small scale: we were able to iterate Script III so that it cycled through a list of six plasma proteins; and to iterate Script IV so that it cycled through a list of expected modifications. The idea of iterating scripts has been included in the new section of Results and Discussion ('Scope for extending the present study'). It has also been made clear that iteration was done in the present study.

I miss the aim of the study

Response: Our primary aim was to evaluate dependent peptide searching as a method for characterising modified proteins. Our secondary aim was to develop visualisation tools. The Abstract, Introduction and Summary have been revised so as to better convey the aims and structure of the study.

Which are scenarios where the tools will be of help?

Response: We envisage the tools as being useful for characterising proteins that have been exposed to enzyme activities or reactive small molecules. If modifications are unique to a given test sample, then the more advanced tools may be able to pick them out. Possible applications have been mentioned at the end of the introduction. The idea that some of the tools are hypothesis-generating while others are hypothesis-testing has also been mentioned.

Does it target the investigation of samples containing one protein or simple mixtures, or also complex samples with thousands of proteins? If the latter was the case, what would the analysis procedure be?

Response: Each script targets a single protein but in theory could be iterated to cycle through a list of proteins (see earlier answer). In practice, this would require a way of cataloguing multiple graphics. An analytical procedure has been proposed in the new section of Results and Discussion ('Scope for extending the present study').

What about the scripts\' potential to visualize in vivo PTMs? This would be very interesting to a much broader readership.

Response: We agree that the visualisation of in vivo PTMs would be an impactful next step. The idea has been mentioned in the new section of Results and Discussion ('Scope for extending the present study').

Another rather simple enhancement would be to look into the identify of the different mass shifts. They could be compared to UniMod/ResID databases and the putative names of the modifications could be extracted, and then for instance shown as word cloud.

Response: Automating the identification in this way could be very powerful, but direct annotation of the plots would have to be done carefully so as not to obscure data. We like the idea of the word cloud. Ways of annotating the visualisations have been proposed in the new section of Results and Discussion ('Scope for extending the present study'). Publications describing Unimod and RESID have been cited.

The introduction would benefit from a short comparison of open database search and dependent search, including their challenges and advantages

Response: The difference between open database searches and spectral pair methods has been explained. The advantages and limitations of dependent peptide searching have been made clear.

I am missing a short description about the flexibility of the scripts to vary the visualizations and/or to extend them to include other information.

Response: We hope that the new section of Results and Discussion ('Scope for extending the present study') addresses the reviewer's concern.
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